To hear about similar clinical trials, please enter your email below
Trial Title:
MRI Contrast Clearance Analysis for Glioma Grading and Genotyping
NCT ID:
NCT06018870
Condition:
Glioma
Conditions: Official terms:
Glioma
Conditions: Keywords:
Glioma
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Other
Summary:
Gliomas are the most common primary brain tumor. Gliomas with different grades have
different clinical behaviors that determine treatment planning and patient prognosis in
clinical practice. In the 2021 World Health Organization (WHO) classification of tumors
for the central nervous system, glioma genotyping was considered the most relevant
information for neuroradiologists. The isocitrate dehydrogenase (IDH) genotype and 1p/19q
codeletion status are two essential molecular markers that divide glioma into three
groups: IDH wild-type, IDH mutant with 1p/19q non-codeletion, and IDH mutant with 1p/19q
codeletion.
MRI contrast clearance analysis (CCA) is based on T1 delayed-contrast subtraction map,
Blue/tumor regions in CCA represent efficient clearance of contrast from the tissue
(delayed signalearly signal).
However, there are not any reports on the role of MRI CCA in glioma grading and
genotyping, Thus, We hypothesized that the proportion of blue/red region and their
histogram analyses, which could be acquired for predicting IDH genotypes and 1p/19q
codeletion in gliomas, and to assess the application of CCA in glioma grading.
Detailed description:
This is a single-center bidirectional cohort study. The subjects of this study were
patients diagnosed as glioma by pathological biopsy. Patients with suspicious mass will
be performed extra 30 and 60 min after contrast agent application delayed T1-weighted
sequences as same as before. Then enter the next experimental stage. (1) Image format
conversion; (2) Registration;(3) Subtraction;(4) ROI segmentation;(5) ROI histogram
analyses. Histogram parameters of blue and red ROI includes 1st、10th 、90th and 99th
percentiles, mean, median, variance, skewness, and kurtosis.
Finally, statistical methods were used to determine whether those parameters was
statistically significant for IDH mutation status、1p/19q codeletion status and tumor
grading.
Criteria for eligibility:
Study pop:
The subjects are not restricted by gender and age. For details, please refer to the
"criteria" column.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Patients with brain space -occupying lesions, have not yet undergone antitumor
therapy;
- MRI with T1-contract delayed sequence was performed less than 2 weeks before
surgery;
- Definite histopathologic diagnosis of glioma.
Exclusion Criteria:
- WHO 1 gliomas and other non-glioma brain tumors;
- Poor image quality and heavy artifact affect the subsequent image processing.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Sang Zifan
Address:
City:
Chongqing
Zip:
400042
Country:
China
Status:
Recruiting
Contact:
Last name:
Zifan Sang, M.M
Phone:
+8618379873389
Email:
952034224@qq.com
Start date:
June 1, 2023
Completion date:
June 30, 2024
Lead sponsor:
Agency:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Agency class:
Other
Source:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06018870
